Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced findings from the landmark OPTION study1 demonstrating that patients with Sorin dual-chamber implantable cardioverter defibrillators experienced a significantly lower incidence of inappropriate shocks compared with patients with standard single-chamber devices (4.3 percent vs.10.3 percent, p=0.015). The study also found that there was no difference in all-cause mortality between the two grou…
Fuente : http://www.eurekalert.org/pub_releases/2013-05/s-s…
Hacer un comentario